Navigation Links
Einstein researcher awarded prestigious cancer research grant
Date:5/12/2010

May 11, 2010 (BRONX, NY) Matthew Gamble, Ph.D., assistant professor of molecular pharmacology at Albert Einstein College of Medicine of Yeshiva University, has been awarded a $200,000 Kimmel Scholar Award. He is one of 15 U.S. scientists selected this year by the Kimmel Scholar program, created in 1997 to advance the careers of promising young scientists involved in cancer research. The $200,000 award will fund Dr. Gamble's innovative research for the next two years.

Dr. Gamble is exploring two families of proteins that interact abnormally in cancer, leading to increased cell division. The research could lead to more targeted drug treatments.

One protein family that Dr. Gamble is studying, called poly(ADP-ribose) polymerases, or PARPs, regulates DNA repair and gene expression, the process through which genes make proteins. Members of the other class of proteins all possess the same "macro domain" a stretch of amino acids that binds to poly(ADP-ribose), the molecule produced by PARPs. The interactions between these two families of proteins influence the ability of cancer cells to grow, but the mechanism is still unknown.

Drugs are now being developed that kill certain types of cancer cells (including breast and ovarian) by inhibiting PARPs, while leaving normal cells unscathed. However, scientists do not yet completely understand why these drugs are effective against some tumors but not others. Since levels of proteins with macro domains are often abnormally expressed in cancer cells, better understanding the interplay between macro domains and PARPs may allow doctors to test cancer patients' macro domain status to determine if they could benefit from taking a PARP inhibitor.

"This award will be crucial to learning how these proteins interact across the genome and how these interactions are disturbed in cancer," Dr. Gamble said.

The 33-year-old Dr. Gamble says that as a new principal investigator at Einstein, he has greatly benefited from his interactions with key faculty, including Susan Band Horwitz, Ph.D., and Charles Rubin, Ph.D., co-chairs of molecular pharmacology.

"Dr. Gamble's work in understanding the interaction between PARPs and macro domain proteins may lead to new treatments for cancer," said Dr. Horwitz. "He's an outstanding young scientist who is very collaborative, and we're fortunate to have recruited him."


'/>"/>

Contact: Deirdre Branley
sciencenews@aecom.yu.edu
718-430-2923
Albert Einstein College of Medicine
Source:Eurekalert  

Related biology news :

1. Einstein researcher receives NIH grant to explore epigenetic regulation of the human genome
2. Einstein researchers receive grants totaling $700,000 for innovative breast cancer research
3. Feinstein researchers develop new genetic method and identify novel genes for schizophrenia
4. In scientific first, Einstein researchers correct decline in organ function associated with old age
5. Einstein researchers develop a new way to study how breast cancer spreads
6. Einstein researchers develop technique to count messages made by single genes
7. Einstein scientists receive $10 million NIH grant
8. Empire State Stem Cell Board awards $12.7 million to Albert Einstein College of Medicine
9. Einstein and Pitt researchers develop new TB test that will dramatically cut diagnosis time
10. NIH funds research center for womens reproductive health at Einstein
11. Einstein researchers devise a fast and sensitive way to detect ricin
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Einstein researcher awarded prestigious cancer research grant
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... CA (PRWEB) , ... June 23, 2016 , ... ... software, is exhibiting at the Pennsylvania Convention Center and will showcase its product’s ... conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials ...
(Date:6/23/2016)... June 22, 2016  Amgen (NASDAQ: AMGN ... QB3@953 life sciences incubator to accelerate the ... shared laboratory space at QB3@953 was created to help ... obstacle for many early stage organizations - access to ... sponsorship, Amgen launched two "Amgen Golden Ticket" awards, providing ...
(Date:6/22/2016)... , June 22, 2016 Research and ... Global Markets" report to their offering. ... billion in 2014 from $29.3 billion in 2013. The market is ... of 13.8% from 2015 to 2020, increasing from $50.6 billion in ... projected product forecasts during the forecast period (2015 to 2020) are ...
Breaking Biology Technology: